Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 5/20 | 0.49 |
| ▸ | RAB9A | P51151 | 5/20 | 0.49 |
| ▸ | F10 | P00742 | 2/20 | 0.48 |
| ▸ | F2 | P00734 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.46 |
| ▸ | TSHR | P16473 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | CES2 | O00748 | 1/20 | 0.44 |
| ▸ | CES1 | P23141 | 1/20 | 0.44 |
| ▸ | PLK1 | P53350 | 1/20 | 0.44 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.44 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL177726 | 0.83 | NPSR1 (0.55) | NPC1RAB9AALDH1A1KMT2AMEN1 | |
| SCHEMBL30416225 | 0.82 | NPC1 (0.70) | HDAC8HDAC6NPC1RAB9AALDH1A1 | |
| SCHEMBL3850447 | 0.82 | NPC1 (0.70) | HDAC8HDAC6NPC1RAB9AALDH1A1 | |
| SCHEMBL3995095 | 0.82 | SMN1; SMN2 (0.52) | NPC1RAB9AALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL289656 | 0.82 | KMT2A (0.57) | NPC1RAB9AALDH1A1KMT2AMEN1 | |
| Hydrochloric Acid SCHEMBL30102161 | 0.81 | NPC1 (0.68) | HDAC8HDAC6NPC1RAB9AALDH1A1 | |
| SCHEMBL177641 | 0.81 | SMN1; SMN2 (0.55) | NPC1RAB9AALDH1A1KMT2AMEN1 | |
| SCHEMBL1490845 | 0.80 | L3MBTL1 (0.61) | NPC1RAB9AALDH1A1KMT2AMEN1 | |
| SCHEMBL28212201 | 0.79 | MEN1 (0.65) | HDAC8HDAC6NPC1RAB9AF10 | |
| SCHEMBL7053844 | 0.79 | HDAC8 (0.73) | HDAC8HDAC6NPC1RAB9AF10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12378250-B2 | Tricyclic compound as IRAK4 inhibitor | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2025-08-05 | — | — | US | disclosed |
| EP-3885348-B1 | NOVEL TRICYCLIC COMPOUND AS IRAK4 INHIBITOR | KOREA RES INST CHEMICAL TECH (KR) | 2025-02-12 | — | — | EP | disclosed |
| US-20220009933-A1 | NOVEL TRICYCLIC COMPOUND AS IRAK4 INHIBITOR | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2022-01-13 | — | — | US | disclosed |
| EP-3885348-A1 | NOVEL TRICYCLIC COMPOUND AS IRAK4 INHIBITOR | Korea Research Institute of Chemical Technology (KR) | 2021-09-29 | — | — | EP | disclosed |
| US-9943519-B2 | Pharmaceutical compounds | GENENTECH, INC. (US) | 2018-04-17 | — | — | US | disclosed |
| US-9562033-B2 | Inhibitors of viral replication, their process of preparation and their therapeutical uses | LABORATOIRE BIODIM (FR) | 2017-02-07 | — | — | US | disclosed |
| US-20160152632-A9 | PHARMACEUTICAL COMPOUNDS | PIRAMED LIMITED (GB) | 2016-06-02 | — | — | US | disclosed |
| US-20160039783-A1 | Inhibitors of Viral Replication, Their Process of Preparation and Their Therapeutical Uses | HIVIH (FR) | 2016-02-11 | — | — | US | disclosed |
| EP-2903983-A1 | INHIBITORS OF VIRAL REPLICATION, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES | LABORATOIRE BIODIM (FR) | 2015-08-12 | — | — | EP | disclosed |
| US-20140323487-A1 | Novel Compounds As Antagonists Or Inverse Agonists At Opioid Receptors | GLAXOSMITHKLINE LLC | 2014-10-30 | — | — | US | disclosed |
| US-20090062317-A1 | MEDICINAL USE OF RECEPTOR LIGANDS | 7TM PHARMA A/S (DK) | 2009-03-05 | — | — | US | disclosed |
| EP-2020404-A1 | Cyanomethyl substituted N-Acyl Tryptamines | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-02-04 | — | — | EP | disclosed |
| WO-2009013335-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-01-29 | — | — | WO | disclosed |
| EP-2001880-A2 | HETEROBICYCLIC PYRAZOLE COMPOUNDS AND METHODS OF USE | Array Biopharma, Inc. (US) | 2008-12-17 | — | — | EP | disclosed |
| WO-2008086158-A1 | BENZODIHYDROQUINAZOLINE AS PI3 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-07-17 | — | — | WO | disclosed |
| WO-2008077597-A1 | 1-AMINOMETHYL- L- PHENYL- CYCLOHEXANE DERIVATIVES AS DDP-IV INHIBITORS | NOVARTIS AG (CH) | 2008-07-03 | — | — | WO | disclosed |
| US-20080076758-A1 | 1S,4S)-2-((2-(1H-indazol-4-yl)-4- morpholinothieno[3,2-d]pyrirnidin-6- yl)methyl)-5-methylsulfonyl-2,5- diaza-bicyclo[2.2.1]heptane; 2-(6-fluoropyridin-3-yl)-6-((4- methylsulfonylpiperazin-1-yl)methyl)-4- morpholinothieno[3,2-d]pyrimidine; treats cancer mediated by pik3 kinase; enzyme inhibitors | PIRAMED LIMITED (GB) | 2008-03-27 | — | — | US | disclosed |
| WO-2007127175-A2 | PHARMACEUTICAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-11-08 | — | — | WO | disclosed |
| US-20070238726-A1 | Heterobicyclic pyrazole compounds and methods of use | GENENTECH, INC. | 2007-10-11 | — | — | US | disclosed |
| WO-2007103308-A2 | HETEROBICYCLIC PYRAZOLE COMPOUNDS AND METHODS OF USE | ARRAY BIOPHARMA INC. (US) | 2007-09-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12378250-B2 | Tricyclic compound as IRAK4 inhibitor | IRAK4, IRAK1, IRAK2 | HDAC8 131/4885HDAC6 301/4885NPC1 1453/4885 |
| US-20080076758-A1 | 1S,4S)-2-((2-(1H-indazol-4-yl)-4- morpholinothieno[3,2-d]pyrirnidin-6- yl)methyl)-5-methylsulfonyl-2,5- diaza-bicyclo[2.2.1]heptane; 2-(6-fluoropyridin-3-yl)-6-((4- methylsulfonylpiperazin-1-yl)methyl)-4- morpholinothieno[3,2-d]pyrimidine; treats cancer mediated by pik3 kinase; enzyme inhibitors | PIK3CA, PIK3CD, PIK3CB | HDAC8 1296/4885HDAC6 2964/4885NPC1 1789/4885 |
| US-20220009933-A1 | NOVEL TRICYCLIC COMPOUND AS IRAK4 INHIBITOR | IRAK4, IRAK1, IRAK2 | HDAC8 116/4885HDAC6 312/4885NPC1 1524/4885 |
| US-20070238726-A1 | Heterobicyclic pyrazole compounds and methods of use | ROR1, CYP11B1, CYP11B2 | HDAC8 3010/4885HDAC6 2092/4885NPC1 2180/4885 |
| US-20140323487-A1 | Novel Compounds As Antagonists Or Inverse Agonists At Opioid Receptors | OPRL1, OPRM1, OPRK1 | HDAC8 2033/4885HDAC6 1298/4885NPC1 3467/4885 |
| US-20090062317-A1 | MEDICINAL USE OF RECEPTOR LIGANDS | MCHR1, MCHR2, MC1R | HDAC8 2957/4885HDAC6 2423/4885NPC1 703/4885 |
| US-20160039783-A1 | Inhibitors of Viral Replication, Their Process of Preparation and Their Therapeutical Uses | POLRMT, MAVS, EIF2AK2 | HDAC8 1454/4885HDAC6 1930/4885NPC1 1277/4885 |
| US-20160152632-A9 | PHARMACEUTICAL COMPOUNDS | PIK3CA, PIK3CD, AKT3 | HDAC8 1402/4885HDAC6 1105/4885NPC1 250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.